Breakthrough Gene Therapy Slows Huntington's Disease Progression by 75%

For the first time, researchers have successfully slowed the progression of Huntington's disease, a hereditary neurodegenerative disorder, by 75% through an innovative gene therapy known as AMT-130. Conducted by uniQure in collaboration with University College London, the clinical trial involved 29 patients and demonstrated that the therapy could extend the quality of life for individuals affected by this devastating condition. Huntington's disease, caused by a mutation in the HTT gene, typically leads to severe cognitive and motor decline, with symptoms usually manifesting in mid-adulthood and resulting in death within 10 to 30 years.

Gene therapy shows a breakthrough in slowing Huntington’s disease progressionGizmodoNew York PostLive ScienceGene Therapy Breakthrough Slows Huntington’s Disease Progression by 75%Historic Breakthrough: Gene Therapy Shows Promise in Slowing Huntington Disease ProgressionWISN - Milwaukee NewsNew Tang Dynasty

The trial, which lasted three years, involved a complex surgical procedure where AMT-130 was administered directly into the brain. This gene therapy utilizes a harmless virus to deliver genetic material that silences the mutant huntingtin protein responsible for neuronal damage. Patients receiving the high dose of AMT-130 experienced a significant reduction in disease progression compared to a matched control group, with results indicating that declines expected over one year would instead take four years.

Huntington’s Disease Gene Therapy BreakthroughBreakthrough Gene Therapy Shows Hope for Huntington’s Disease as Landmark Trial Slows ProgressionGene therapy shows a breakthrough in slowing Huntington’s disease progressionBreakthrough Gene Therapy Offers Hope as Huntington's Disease Treatment Shows 75% Progression SlowdownGene therapy slows Huntington’s Disease progression by 75%Gene Therapy Breakthrough Slows Huntington’s Disease Progression by 75%Live ScienceGene therapy AMT-130 slows Huntington’s progression by 75%

The study's primary endpoint was assessed using the composite Unified Huntington’s Disease Rating Scale (cUHDRS), which evaluates motor, cognitive, and functional abilities. The high-dose group showed a 75% slowing of disease progression, while also demonstrating a 60% reduction in the decline of daily functional capacity.

Gene therapy AMT-130 slows Huntington’s progression by 75%

The findings have been described as "spectacular" by Professor Sarah Tabrizi, director of the University College London Huntington’s Disease Centre. She emphasized the potential for AMT-130 to provide patients with decades of "good quality life." The therapy's ability to preserve brain function and independence is particularly significant for families who have witnessed the devastating effects of the disease across generations.

United Press International (UPI)

Jack May-Davis, a participant in the trial whose family has a history of Huntington's disease, expressed his overwhelming joy at the breakthrough. He noted that the treatment allows him to envision a future that seems "a little bit brighter," contrasting sharply with the grim outlook previously associated with the diagnosis.

CNBC TV18

While the results are promising, experts caution that the data are preliminary and not yet peer-reviewed. The therapy was generally well-tolerated, with most side effects related to the surgical procedure itself. UniQure plans to submit an application for accelerated approval to the U.S. Food and Drug Administration (FDA) in early 2026, with hopes for availability later that year.

ScienceAlert

The success of AMT-130 not only represents a significant advancement in the treatment of Huntington's disease but also opens the door for similar gene therapies targeting other neurodegenerative disorders. As researchers continue to explore the potential of gene therapy, the Huntington's community remains hopeful for a future where the disease can be effectively managed or even prevented.

Historic Breakthrough: Gene Therapy Shows Promise in Slowing Huntington Disease ProgressionBreakthrough Gene Therapy Offers Hope as Huntington's Disease Treatment Shows 75% Progression SlowdownWoman's WorldWISN - Milwaukee NewsGene Therapy Breakthrough Slows Huntington’s Disease Progression by 75%Gene therapy shows a breakthrough in slowing Huntington’s disease progressionLADbibleScienceAlert

The development of AMT-130 marks a pivotal moment in the fight against Huntington's disease, providing a glimmer of hope for thousands of patients and their families. As the therapy moves closer to regulatory approval, the medical community is optimistic about its potential to transform the treatment landscape for this devastating genetic disorder.

Gene Therapy Breakthrough Slows Huntington’s Disease Progression by 75%